For Healthcare Professionals

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation


About the study

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies
  2. ECOG Performance Status of 0 or 1
  3. At least one measurable lesion as defined by RECIST 1.1
  4. Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion


Exclusion Criteria:

  1. Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
  2. Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible
  3. Clinically significant cardiac disease or risk factors at screening
  4. A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-888-669-6682Email iconEmail Study Center

Study’s details


Carcinoma, Non-Small-Cell Lung,KRAS G12C Mutant Solid Tumors,Carcinoma, Colorectal,Cancer of Lung,Cancer of the Lung,Lung Cancer,Neoplasms, Lung,Neoplasms, Pulmonary,Pulmonary Cancer,Pulmonary Neoplasms

Age (in years)



Phase 1/Phase 2

Participants needed


Est. Completion Date

Jan 8, 2027

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.